Immunogenicity of human papillomavirus recombinant vaccine in children with CKD

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 5, 2016, Pages 776-784

  Nelson, Delphine R ^a   Neu, Alicia M ^a   Abraham, Alison ^b   Amaral, Sandra ^c   Batisky, Donald ^d   Fadrowski, Jeffrey J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody formation; Child; Chronic kidney disease; Clinical immunology; Humans; Immunosuppression; Kidney transplantation; Papillomavirus infections; Papillomavirus vaccines; Renal dialysis

Indexed keywords

ABATACEPT; CYCLOSPORIN; IMMUNOGLOBULIN G; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; TACROLIMUS; WART VIRUS VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; DIALYSIS; FEMALE; GENOTYPE; HEADACHE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE CONTUSION; KIDNEY TRANSPLANTATION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAIN; SCHOOL CHILD; SENSITIVITY ANALYSIS; YOUNG ADULT; BLOOD; HEMODIALYSIS; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNIZATION; IMMUNOLOGY; TIME FACTOR;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION SCHEDULE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 85007161427     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09690915     Document Type: Article

References (36)

1. CDC: CDC Cervical Cancer Statistics, Atlanta, Georgia, CDC, 2014
2. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT: Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 12: 959–969, 2005
3. Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 24[Suppl 3]: 11–25, 2006
4. Brunner FP, Landais P, Selwood NH; European Dialysis and Transplantation Association-European Renal Association: Malignancies after renal transplantation: The EDTA-ERA registry experience. Nephrol Dial Transplant 10[Suppl 1]: 74–80, 1995
5. Kessler M, Jay N, Molle R, Guillemin F: Excess risk of cancer in renal transplant patients. Transpl Int 19: 908–914, 2006
6. Leigh IM, Glover MT: Skin cancer and warts in immunosup-pressed renal transplant recipients. Recent Results Cancer Res 139: 69–86, 1995
7. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant 4: 905–913, 2004
8. Merck GmbH: Gardasil Product Insert 9682302, Merck GmbH, Whitehouse Station, New Jersey, 2006
9. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, Basile C: Hepatitis B virus infection in chronic uremia: Long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 23: 537–542, 1994
10. Sezer S, Ozdemir FN, Güz G, Arat Z, Colak T, Sengul S, Turan M, Haberal A, Erdal R: Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 32: 607–608, 2000
11. Schulman SL, Deforest A, Kaiser BA, Polinsky MS, Baluarte HJ: Response to measles-mumps-rubella vaccine in children on dialysis. Pediatr Nephrol 6: 187–189, 1992
12. Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, Camsari T: The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 37: 71–76, 2003
13. Suga T, Niki H, Niikura M, Matsumoto Y, Nishimura T, Nakajima K, Miyazaki M, Endoh M, Nomoto Y, Sakai H: Influenza antibody titers after vaccination of chronic renal failure patients; before and during hemodialysis, or on continuous ambulatory peritoneal dialysis. Tokai J Exp Clin Med 15: 245–251, 1990
14. Fuchshuber A, Kühnemund O, Keuth B, Lütticken R, Michalk D, Querfeld U: Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 11: 468– 473, 1996
15. Krüger S, Müller-Steinhardt M, Kirchner H, Kreft B: A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis 38: 1264– 1270, 2001
16. Fivush BA, Neu AM: Immunization guidelines for pediatric renal disease. Semin Nephrol 18: 256–263, 1998
17. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL: New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20: 629–637, 2009
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
19. Muñoz N, Manalastas R Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 373: 1949–1957, 2009
20. StataCorp.: STATA Statistical Software,College Station, TX, Statacorp., 2013
21. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr., Reisinger KS; Protocol 016 Study Group: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118: 2135–2145, 2006
22. Smith JM, Martz K, Blydt-Hansen TD: Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: A report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant 17: 149–157, 2013
23. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/ Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928–1943, 2007
24. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R; FUTURE I/II Study Group: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 341: c3493, 2010
25. Vaziri ND, Pahl MV, Crum A, Norris K: Effect of uremia on structure and function of immune system. J Ren Nutr 22: 149– 156, 2012
26. Chonchol M: Neutrophil dysfunction and infection risk in end-stage renal disease. Semin Dial 19: 291–296, 2006
27. Dalrymple LS, Go AS: Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1487–1493, 2008
28. Fadrowski JJ, Furth SL: Varicella zoster virus: Vaccination and implications in children with renal failure. Expert Rev Vaccines 3: 291–298, 2004
29. Esposito S, Mastrolia MV, Prada E, Pietrasanta C, Principi N: Vaccine administration in children with chronic kidney disease. Vaccine 32: 6601–6606, 2014
30. Gomez-Lobo V, Whyte T, Kaufman S, Torres C, Moudgil A: Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. Pediatr Transplant 18: 310–315, 2014
31. Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A: Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant 13: 2411– 2417, 2013
32. Schiller JT, Lowy DR: Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 200: 166– 171, 2009
33. Brown D, Müller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A: Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papil-lomaviruse types 16 and 18. Vaccine 32: 5880–5887, 2014
34. Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT: The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 7: 230–238, 2011
35. Meeuwis KA, Hilbrands LB, IntHout J, Slangen BF, Hendriks IM, Hinten F, Christiaans MH, Quint WG, van de Kerkhof PC, Massuger LF, Hoitsma AJ, van Rossum MM, Melchers WJ, de Hullu JA: Cervicovaginal HPV infection in female renal transplant recipients: An observational, self-sampling based, cohort study. Am J Transplant 15: 723–733, 2015
36. Chockalingam R, Downing C, Tyring SK: Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med 4: 1229–1239, 2015